Current attitudes and preconceptions on newborn genetic screening in the Chinese reproductive-aged population

Xin Wang†, Xian‑Wei Guan†, Yan‑Yun Wang, Zhi‑Lei Zhang, Ya‑Hong Li, Pei‑Ying Yang, Yun Sun* and Tao Jiang*

Abstract

Purpose: Newborn screening (NBS) applications are limited as they can only cover a few genetic diseases and may have false positive or false negative rates. A new detection program called newborn genetic screening (NBGS) has been designed to address the potential defects of NBS. This study aimed to investigate the perceptions, acceptance, and expectations of childbearing people related to NBGS to provide the basis for the targeted improvement in the NBGS program carried out in Hospitals.

Methods: A questionnaire with 20 items was designed on www.wjx.cn. Individuals who came to the Nanjing maternity and child health care Hospital for consultation from June 2021 to August 2021 participated in the survey. The data of the study was arranged properly and analyzed after the investigation.

Results: A total of 1141 valid questionnaires were collected in the survey, in which the average age of the participants was 31 (± 4) years, and a 1:4 ratio of males to females. Additionally, 65.12% of the participants possessed a bachelor's degree or above qualification. Overall, 50.57% of participants had an annual household income of 100,000–250,000 RMB, while about 86.68% of the participants supported the development of NBGS. The participation cost to pay for NBGS depended on the family incomes; about 59.42% of them were willing to pay a participation fee of 1000–2000 RMB.

Conclusion: Our research provisionally demonstrated that the residents generally supported the use of NBGS, especially those with higher educational degrees, but the understanding of the genetic diseases and NBGS among the low-educated population still needs to be strengthened.

Keywords: Newborn screening, Genetic screening, Inherited metabolic disorder, Rare disease

Introduction

The traditional newborn screening (NBS) program has a developmental history of more than 50 years [1]. It is a successful public health program that functions to find severe disorders early by detecting various biochemical indicators from heel blood samples in newborns [2]. Early detection, diagnosis, and intervention of severe disorders can help prevent deaths and improve children's quality of life with lethal newborn diseases [3].

Currently, the most commonly used method is the application of tandem mass spectrometry (MS–MS), which has a significant advantage in cost-effectiveness and high throughput. Unlike other previously used methods, it can effectively detect more than 40 inherited metabolic diseases (IMD) [4–7]. IMD of genetic diseases specifically refers to a type of genetic disease with various defects in the metabolic function, most of which are
single-gene genetic diseases. These include macromolecular metabolic disorders such as lysosomal storage and mitochondrial diseases. It also includes small-molecule metabolic disorders involving amino acids, organic acids, and fatty acids [8]. Nonetheless, due to several drawbacks, such as false-positive rates and a restricted number of diseases associated with existing detection methods [9, 10], the IMD of newborns that can be detected is highly limited.

With the transformation of society, which includes advances in medical research and economic growth, emphasis has been given to prenatal and postnatal care services, and the demand for congenital disability prevention networks has increased. There is an immediate need to develop a comprehensive NBS program capable of detecting a more significant number of diseases with high accuracy [9]. It is also intended to promote early screening, diagnosis and treatment and improve the newborn population’s quality of life. Next-generation sequencing (NGS) technology is used in newborn genetic screening (NBGS), which includes disease-targeted gene package panel sequencing, whole-exome sequencing, and whole-genome sequencing [11]. The NBGS can functionally detect the pathogenic genes of different diseases. This has greatly boosted the detection rate and has played a key role in excluding screening in some diseases based on biochemical testing. NBGS has various restrictions that may impede its implementation, including difficulties in interpreting variant sites, the privacy of genetic information, the higher cost, the possibility of missing some diseases that require biochemical identification, and the risk of overmedication caused by the rise in diseases [11]. The BabySeq exome-sequencing project (Boston, USA), the NC NEXUS exome-sequencing project (North Carolina, USA), the NBSeq project (California, USA), and the NESTS genetic screening project (Beijing, China) have been reported [12–17]. The findings of these programs have demonstrated that genetic screening can detect a wide variety of diseases and specific variants that NBS cannot detect and affirm the actual value of genetic screening. In addition, a detailed analysis was carried out on the inclusion conditions of the gene screening diseases and the interpretation criteria of the results [18, 19], which has provided a sound basis for further exploration of the clinical applications of NBGS.

It is crucial to determine if the NBGS program can be successfully implemented in China based on the acceptability of the relevant clinical population. Population support is critical for the rapid development of the project, but there are still no relevant reports published in China yet. Therefore, based on the existing genetic screening foundation, this study anticipated surveying the clinically relevant populations. Following that, through analysis of the Chinese population’s cognition and acceptance of the NBGS projects, the clinical feasibility of the NBGS will be systematically evaluated to promote the clinical development of this technology.

**Materials and methods**

**Questionnaire design**

A questionnaire on the NBGS was designed with 20 different items. The questionnaire included the various basic information such as gender, age, education, family income of the participants, their understanding, views on the NBS program and genetic diseases, and their willingness and expectations of including an additional genetic screening in the NBS program. The Research Ethics Committee of the Women’s Hospital of Nanjing Medical University (2021KY-071) approved the present study.

**Study population**

After obtaining the participant’s consent, we performed a questionnaire survey on several genetic screening-related problems for Nanjing women of reproductive ages who visited the Nanjing Maternity and Child Health Care Hospital’s genetic therapy clinic. A total of 1141 valid questionnaires were acquired after excluding the non-Nanjing population.

**Statistical analyses**

The data is expressed as the median±standard deviation (±SD). A Chi-square test was used for the statistical comparisons. A P-value of <0.05 was considered statistically significant (*P<0.05; **P<0.01; ***P<0.001).

**Results**

**Demographic information of the participants**

1141 individuals who intended to have a baby or a second child were given a questionnaire (Additional file 1: Table S1) to assess the population’s perspectives on the NBGS. The data indicated that most participants who came for consultation were approximately 30 years old. The average age of the participants was 31 (±4) years, with a male to female ratio of 1:4 (Fig. 1). About 99.74% of the participants did not have any family history of the genetic diseases. Among all the study participants, 65.12% possessed a bachelor’s degree or above qualification. While half of the participants had an annual household income of around 100,000–250,000 RMB (50.57%) (Table 1).

**Awareness of NBS**

Most families had a relatively sufficient understanding of the genetic diseases and were aware of the aims of the NBS project (Table 2). When the NBS results were abnormal, most participants could make the correct
choice regarding the time, willing to actively cooperate with further testing, which indicated a positive attitude towards NBS (99.12%).

**Expectations for NBS**

Additionally, regarding the further development of NBS, most of the participants gave a positive answer (81.51%) on whether there was a need to further increase the number of NBS diseases. The people who supported the NBGS were considered the prominent supporters (87.06%), and about half of the remaining people (44.08%) wanted to seek the doctor’s opinion first.

In terms of increasing the number of diseases, most participants (71.96%) assumed that the more the better.

---

**Table 1** Characteristics of participants and gender

|                         | Total (n = 1141, 100%) | Male (n = 271, 23.75%) | Female (n = 870, 76.25%) | Value | P       |
|-------------------------|------------------------|------------------------|--------------------------|-------|---------|
| **Age (years old)**    |                        |                        |                          |       |         |
| ≤ 24                    | 41 (3.59%)             | 9 (3.32%)              | 32 (3.68%)               | 2.942 | P > 0.05|
| 25–29                   | 443 (38.83%)           | 95 (35.06%)            | 348 (40%)                |       |         |
| 30–34                   | 490 (42.94%)           | 121 (44.65%)           | 369 (42.41%)             |       |         |
| ≥ 35                    | 167 (14.64%)           | 46 (16.97%)            | 121 (13.91%)             |       |         |
| **Have you had family history of genetic disease?** | | | | | |
| Yes                     | 3 (0.26%)              | 0 (0.00%)              | 3 (0.34%)                | 0.937 | P > 0.05|
| No                      | 1138 (99.74%)          | 271 (100%)             | 867 (99.66%)             |       |         |
| **Educational background** |                        |                        |                          |       |         |
| Below high school       | 53 (4.64%)             | 12 (4.43%)             | 41 (4.71%)               | 0.509 | P > 0.05|
| High school/technical secondary school | 103 (9.03%) | 22 (8.12%) | 81 (9.31%) |       |         |
| Junior college/Vocational College | 242 (21.21%) | 60 (22.14%) | 182 (20.92%) |       |         |
| Undergraduate or above  | 743 (65.12%)           | 177 (65.31%)           | 566 (65.06%)             |       |         |
| **Family income**       |                        |                        |                          |       |         |
| < 100 thousand RMB      | 187 (16.39%)           | 49 (18.08%)            | 138 (15.86%)             | 0.890 | P > 0.05|
| 100–250 thousand RMB    | 577 (50.57%)           | 134 (49.45%)           | 443 (50.92%)             |       |         |
| 260–400 thousand RMB    | 255 (22.35%)           | 61 (22.51%)            | 194 (22.30%)             |       |         |
| > 400 thousand RMB      | 122 (10.69%)           | 27 (9.96%)             | 95 (10.92%)              |       |         |
| **Nation**              |                        |                        |                          |       |         |
| Han nationality         | 1117 (97.90%)          | 267 (98.52%)           | 850 (97.70%)             | 0.679 | P > 0.05|
| Others                  | 24 (2.10%)             | 4 (1.48%)              | 20 (2.30%)               |       |         |
| **Had any abnormalities in you/your spouse’s fetus during pregnancy?** | | | | | |
| Yes                     | 34 (2.98%)             | 10 (3.69%)             | 24 (2.76%)               | 0.620 | P > 0.05|
| No                      | 1107 (97.02%)          | 261 (96.31%)           | 846 (97.24%)             |       |         |
Approximately 22.52% of the population held a more conservative attitude and believed that 10–50 different types of diseases could be added based on the originally selected diseases. But, in the non-supportive NBGS population, 21.71% of the population believed that there was no need to increase the number of diseases. Moreover, for the detection rate of new diseases added to NBS, the participants (54.78%) considered that a relatively satisfactory NBGS program should have a total detection rate of at least 95%. For the diseases with a very low incidence, the detection rate should reach at least 80% (51.36%). Among them, the people who supported the NBGS generally had higher requirements for the detection rate than the rest of the population. The participants were also willing to bear the costs arising from the increase in diseases, and most of them (59.42%) were willing to pay 1000–2000 RMB. Moreover, we discovered that individuals (26.29%) that supported the NBGS were willing to pay more than others (> 2000RMB), whilst those who were not in favour (30.26%) of the NBGS were more likely to keep lower expenses (< 1000RMB) (Table 3).

**Crowds’ analysis of NBGS supporters**

Approximately 86.68% of participants agreed that it is essential to conduct the NBGS as a supplement to the traditional NBS to ascertain the genetic causes of diseases and intervene promptly (Table 4). There were no significant variations in gender, age, race, genetic background, or life attitudes between those who favoured the NBGS and those who did not or were uncertain. People who supported the NBGS were generally more worried about diagnosing genetic diseases in children that could not be treated.

Significant differences were observed in terms of education level and family income. Among the population that supported the NBGS, a highly-educated population accounted for the substantial part (67.55% vs. 49.34%), while among the non-supportive population, the less-educated population was relatively significant. In addition, it was also found that people with higher education levels had a more explicit attitude towards the proposal of increasing the number of diseases detected by NBS (Fig. 2A). Further, some participants with higher education levels possessed a conservative view about the possible increase in diseases detected in NBS, believing that a moderate increase of 10–50 types was enough (Fig. 2B). Besides, people with low education degrees were more uncertain and pessimistic about adding diseases to the NBS project.

The current study also revealed that individuals who supported the NBGS had a significant proportion of high-income participants (> 400,000 RMB, 11.83% vs. 3.3%) (Table 4). Furthermore, high-income families were more willing than low-income families to tolerate increasing testing costs (Fig. 2C).
Consideration and expectations for NBGS

Regarding the implementation of the NBGS project, participants were more willing to learn about it through face-to-face consultation with doctors (91.76%), followed by brochures and educational videos (59.86%), small lessons for pregnant women (54.51%), and official hospital accounts (50.04%), but seldom choose to search and inquire online by themselves (27.96%). The participants were willing to actively cooperate during the diagnostic processes when the initial screening results were positive (98.51%), and the people who favoured the NBGS were more active (99.70% vs. 90.79%). The participants (98.07%) also desired to know when the suspected pathogenic genes were not related to the clinical manifestations. They (93.69%) were also willing to inform their children about their NBGS results when they became adults and advised them to undertake further carrier screening with their partners before starting a family (Table 5).

As society and science have progressed, people have become more aware and dissatisfied with the existing NBS program. Especially with the NBGS, which may supplement newborn screening and allow them to understand more about congenital diseases.

Discussion

Based on the present study, it was found that the factors that can potentially influence the support of the people for NBGS were mainly related to personal cognition, education, and family income. Among those who did not support NBGS, 49.34% were highly educated, while 23.03% belonged to the low-educated group. Of the participants supporting NBGS, people with high education credentials accounted for 67.55%, whereas those with low education profiles accounted for only 12.23%. Similarly, in the non-supportive NBGS population, 3.3% had an annual family income of more than 400,000 RMB, and 32.89% had an annual family income of less than 100,000 RMB. Participants with a yearly household income of less than 100,000 RMB accounted for only 13.85% of those who supported NBGS. In contrast,

Table 3  Participants’ expectation on undergoing genetic screening

| Is it necessary to undergo genetic screening? | Value | P       |
|--------------------------------------------|-------|---------|
| Total (n = 1141, 100%)                     |       |         |
| Yes (n = 989, 86.68%)                      |       |         |
| No/I don't know (n = 152, 13.32%)          |       |         |

Table 3: Participants’ expectation on undergoing genetic screening

- **Do you think it is necessary to increase the number of diseases in NBS?**
  - Yes: 930 (81.51%) vs. 861 (87.06%) vs. 69 (45.39%)
  - No: 15 (1.31%) vs. 11 (1.11%) vs. 4 (2.63%)
  - P = 0.05

- **How many new diseases do you wish to be added to NBS?**
  - As many and comprehensive as possible: 821 (71.96%) vs. 734 (74.22%) vs. 87 (57.24%)
  - P = 0.05

- **The cost of NBS may increase with the number of screening diseases. How much are you willing to pay for the NBS after expanding the types of diseases?**
  - < 1000 RMB: 181 (15.86%) vs. 135 (13.65%) vs. 46 (30.26%)
  - P = 0.05

- **What is the minimum detection rate for each disease in newborn genetic screening that you can accept?**
  - > 95%: 625 (54.78%) vs. 554 (56.02%) vs. 71 (46.71%)
  - > 75%: 163 (14.28%) vs. 148 (14.96%) vs. 15 (9.87%)
  - > 60%: 102 (8.94%) vs. 87 (8.80%) vs. 15 (9.87%)
  - > 30%: 251 (22.00%) vs. 200 (20.22%) vs. 51 (33.55%)
  - P = 0.05

- **For low onset genetic diseases, the detection rate of genetic screening is low. What is the minimum detection rate for these diseases in newborn genetic screening that you can accept?**
  - > 80%: 586 (51.36%) vs. 519 (52.48%) vs. 67 (44.08%)
  - > 65%: 194 (17.00%) vs. 164 (16.58%) vs. 30 (19.74%)
  - P = 0.05
  - > 50%: 123 (10.78%) vs. 111 (11.22%) vs. 12 (7.89%)
  - > 30%: 238 (20.86%) vs. 195 (19.72%) vs. 43 (28.29%)
those with an annual household income of more than 400,000 RMB accounted for only 11.83% (Table 4).

Our findings also revealed that for the future clinical development of NBGS, it is critical to do an exceptional job sharing relevant NBGS knowledge. The general public must fully comprehend the importance of NBGS development. We observed that participants preferred to learn passively rather than actively to understand NBGS content (Table 5).

China has unveiled a new policy of three-child per family, which has recommended that a couple can have up to three children. Thus, the importance of the NBGS project is not only to efficiently screen out newborn diseases on time but also to combine it with genetic counselling to guide parents in reproducing, which is crucial in producing healthy children. In addition, we also found that the majority (15.57% vs. 8.55%) of the adults (≥ 35 years old) were willing to support the development of NBGS, which

---

**Table 4** Views of different participants on genetic screening

|                                      | Is it necessary to undergo genetic screening? | Value | P     |
|--------------------------------------|----------------------------------------------|-------|-------|
|                                      | Total (n = 1141, 100%) Yes (n = 989, 86.68%) No/I don't know (n = 152, 13.32%) |       |       |
| Gender                               |                                              |       |       |
| Male                                 | 271 (23.75%)                                 | 235 (23.76%) | 36 (23.68%) | 0.00 | P > 0.05 |
| Female                               | 870 (76.25%)                                 | 754 (76.24%) | 116 (76.32%) |       |       |
| Age (years old)                      |                                              |       |       |
| ≤ 24                                 | 41 (3.59%)                                   | 37 (3.74%) | 4 (2.63%) | 5.995 | P > 0.05 |
| 25–29                                | 443 (38.83%)                                 | 380 (38.42%) | 63 (41.45%) |       |       |
| 30–34                                | 490 (42.94%)                                 | 418 (42.27%) | 72 (47.37%) |       |       |
| ≥ 35                                 | 167 (14.64%)                                 | 154 (15.57%) | 13 (8.55%) |       |       |
| Have you had family history of genetic disease? |                                              |       |       |
| Yes                                  | 3 (0.26%)                                    | 3 (0.30%) | 0 (0.00%) | 0.462 | P > 0.05 |
| No                                   | 1138 (99.74%)                                | 986 (99.70%) | 152 (100%) |       |       |
| Nation                               |                                              |       |       |
| Han nationality                      | 1117 (97.90%)                                | 969 (97.98%) | 148 (97.37%) | 0.238 | P > 0.05 |
| Others                               | 24 (2.10%)                                   | 20 (2.02%) | 4 (2.63%) |       |       |
| Had any abnormalities in your/spouse's fetus during pregnancy? |                                              |       |       |
| Yes                                  | 34 (2.98%)                                   | 32 (3.24%) | 2 (1.32%) | 1.680 | P > 0.05 |
| No                                   | 1107 (97.02%)                                | 957 (96.76%) | 150 (98.68%) |       |       |
| If your child is diagnosed with an inherited genetic disease but not treated, will you worry about the aggravation of your child's condition? |                                              |       |       |
| Yes                                  | 1120 (98.16%)                                | 977 (98.79%) | 143 (94.08%) | 16.162 | P < 0.05 |
| No                                   | 21 (1.84%)                                   | 12 (1.21%) | 9 (5.92%) |       |       |
| Educational background               |                                              |       |       |
| Below high school                    | 53 (4.64%)                                   | 38 (3.84%) | 15 (9.87%) | 23.727 | P < 0.05 |
| High school and technical secondary school | 103 (9.03%)                                 | 83 (8.39%) | 20 (13.16%) |       |       |
| Junior college/Vocational College    | 242 (21.21%)                                 | 200 (20.22%) | 42 (27.63%) |       |       |
| Undergraduate or above               | 743 (65.12%)                                 | 668 (67.55%) | 75 (49.34%) |       |       |
| Family income                        |                                              |       |       |
| < 100 thousand RMB                   | 187 (16.39%)                                 | 137 (13.85%) | 50 (32.89%) |       |       |
| 100–250 thousand RMB                 | 577 (50.57%)                                 | 508 (51.37%) | 69 (45.39%) | 40.277 | P < 0.05 |
| 260–400 thousand RMB                 | 255 (22.35%)                                 | 227 (22.95%) | 28 (18.42%) |       |       |
| > 400 thousand RMB                   | 122 (10.69%)                                 | 117 (11.83%) | 5 (3.30%) |       |       |
| If your child is diagnosed with an inherited genetic disease and requires long-term (lifelong) treatment, how do you think it will affect your family life status? |                                              |       |       |
| Decrease the quality of life, increase daily burden and anxiety, and life becomes negative | 267 (23.40%) | 227 (22.95%) | 40 (26.32%) | 0.831 | P > 0.05 |
| Grateful for early detection and treatment for the disease which improves the child's quality of life | 874 (76.60%) | 762 (77.05%) | 112 (73.68%) |       |       |
Fig. 2 Cross-over analysis of the participants. **A** The participants had different education degrees and they differed in opinion regarding whether it was necessary to increase the number of diseases in NBS (Q12). **B** The views of the participants with different education degrees on how many new diseases were added to NBS (Q13). **C** The views of the participants of different family incomes concerning how much they would be willing to pay for the NBS after expanding the types of diseases (Q14).

### Table 5 Participants’ demands after undergoing the genetic screening

| Demand                                                                 | Total (n = 1141, 100%) | Yes (n = 989, 86.68%) | No/I don’t know (n = 152, 13.32%) | Value  | P     |
|------------------------------------------------------------------------|------------------------|-----------------------|-----------------------------------|--------|-------|
| **Is it necessary to undergo genetic screening?**                       |                        |                       |                                   |        |       |
| Total                                                                   |                        |                       |                                   |        |       |
| Yes                                                                    | 989 (86.68%)           | 917 (92.72%)          | 130 (85.53%)                     |        |       |
| No/I don’t know                                                        | 152 (13.32%)           | 72 (6.31%)            | 80 (51.88%)                      |        |       |
| **Which ways would you like to learn more about NBGS? (Multiple options)** |                        |                       |                                   |        |       |
| Consult doctors face to face                                           | 1047 (91.76%)          | 917 (92.72%)          | 130 (85.53%)                     |        |       |
| Brochure or education video of outpatient waiting area                  | 683 (59.86%)           | 599 (60.57%)          | 84 (55.26%)                      |        |       |
| Get online and research by oneself                                     | 319 (27.96%)           | 274 (27.70%)          | 45 (29.61%)                      | 1.781  | > 0.05|
| Study or lecture for pregnant women                                     | 622 (54.51%)           | 549 (55.11%)          | 73 (48.03%)                      | 6.321  | 0.011 |
| The official account of hospital                                        | 571 (50.04%)           | 507 (51.26%)          | 64 (42.11%)                      |        |       |
| Will you actively obtain a genetic diagnosis after a positive genetic screening result? |                        |                       |                                   |        |       |
| Yes, actively carry out a genetic diagnosis to clarify the disease     | 1124 (98.51%)          | 986 (99.70%)          | 138 (90.79%)                     | 71.218 | < 0.05|
| No need, genetic screening is equal to genetic diagnosis               | 17 (1.49%)             | 3 (0.30%)             | 14 (9.21%)                       | 4.403  | 0.036 |
| If your child’s genetic screening results reveal other suspected pathogenic genes, but are not related to the clinical phenotype, would you like to be informed? |                        |                       |                                   |        |       |
| Yes, I need to know                                                     | 1119 (98.07%)          | 978 (98.89%)          | 141 (92.76%)                     | 26.135 | < 0.05|
| Don’t want to know, to reduce the anxiety after knowing the result      | 72 (6.31%)             | 54 (5.46%)            | 18 (11.84%)                      | 9.077  | < 0.05|
| If you know that your children have carried pathogenic genes through genetic screening, will you tell them when they become adults? |                        |                       |                                   |        |       |
| Yes, and recommend them to do a carrier screen with their partner before giving birth to their child | 1069 (93.69%)          | 935 (94.54%)          | 134 (88.16%)                     | 9.077  | < 0.05|
| Will not tell them, to reduce their anxiety after knowing the results   | 72 (6.31%)             | 54 (5.46%)            | 18 (11.84%)                      | 9.077  | < 0.05|
makes us gratified. The benefit of the three-child policy is that the number of advanced maternal age will inevitably increase, while the pregnancy outcomes in older couples have always been a cause for concern [20, 21]. After the project is successfully implemented, older people's support for NBGS will facilitate genetic counselling for advanced maternal age couples.

The actual development of NBGS still needs to go through a relatively long process of exploration, including the specific inclusion of conditions and schemes for the NBGS. Most people believe that more diseases should be included regarding the population's views on the number of diseases screened by NBGS. A small number of people indicated that the suitable amount is enough; this part of the population was also dominated by highly-educated people (Fig. 2), thereby showing a more conservative consideration for supporting the increase in the number of NBGS diseases. The number of diseases that can be screened is limited. As a result, it is crucial to analyze all aspects of the need for early screening, such as the severity of the disease and whether or not it can be treated, because early treatment can improve the prognosis and minimize related morbidity [11, 22, 23]. A strategy for early intervention could potentially generate accurate predictions for disorders affecting infants to children that pose substantial risks but are treatable. Thus, such diseases can be considered the most suitable for the NBGS project inclusion, which will increase the family's program acceptance rate. Simultaneously, care should be taken to avoid including disorders with unknown genotype–phenotype connections, mild phenotypes that may not require intervention, or diseases with late-onset, to avoid the development of "patients in waiting" and the negative effects of overmedicalization [24]. Overmedicalization in this context refers to interventions that are not medically required or evidence-based, which may raise costs and cause concern in these families. The choice of detection technology requires consideration of its cost-effectiveness. In the case of fully considering the national conditions, the detection technology with low cost, simple operation, and short reporting period would be selected [25].

Since the phenotype is not only associated with genotype but also has distinct phenotypic variability, entirely replacing traditional biochemical screening with genetic testing may not be an appropriate screening optimization technique. The organic combination of NBGS and standard biochemical screening may have unexpected effects. The implementation of NBGS requires careful consideration of the above aspects and a comparative analysis of cost-effectiveness before arriving at the best implementation plan that the families ultimately require. In addition, the development of NBGS should also pay attention to ethical issues, especially for genetic counselling, psychological counselling, and carrier information feedback for screen-positive family members. Previous studies have suggested both benefits and risks in feeding information about newborn carriers to newborn families [26, 27]. Nonetheless, we must conduct more appropriate and targeted assessments for different groups and modify the report content based on the evaluation results.

NBGS is a novel concept that has recently been introduced, and it can be considered a significant generation milestone in the field of newborn screening. With the emergence of next-generation sequencing technology, the detection of various inherited diseases is no longer limited to biochemical methods. Thus, analyzing the various diseases from the genetic perspective could help assist in intervention, diagnosis, and treatment. For the best choice of NBGS methods, it is still important to compare and evaluate the cost, detection cycle, DNA coverage, ease of operation, and the population they can be used on. The clinical development of NBGS is also an inevitable trend, but it still needs continuous improvement in the advancement process for everyday use.

We understood the attitudes and beliefs of the reproductive-aged population towards NBGS and found that most individuals were willing to accept NBGS programs. Notably, those with a high level of education and income provide a solid foundation for the future development of NBGS. However, this study also has limitations. The number of male participants was limited, making it difficult to effectively assess the cognitive differences between males and females on many issues.

When "global health" and "social justice" have taken on particular relevance due to the COVID 19 pandemic and vaccine processes, the development of NBGS seems more controversial. In light of current findings, people are motivated to improve the existing NBS on the one hand because they foresee future improvements in their quality of life. The cost of NBGS testing, on the other hand, may hinder the development of NBGS in countries with low-income and lower literacy rates. Yet, the development of NBGS may be reasonably simple and easy for high-income countries and for educated people who understand its importance for the family in the longer term. However, if we want to carry out NBGS in low- and middle-income countries, the income level of low- and middle-income people still needs to be mainly considered, which comprises most of the population. As a middle-income country with a large population, China should consider three leading solutions: (i) improving testing technology to reduce testing costs, (ii) improving the part of medical insurance for NBS, and (iii) giving appropriate government subsidies until the program has been highly accepted and appreciated by the community. The experience and
results obtained in implementing and developing NBGS in China may provide reference and help develop NBGS in other developing countries. Prenatal and postnatal care should be paid more attention to the long-term development of human beings. The smooth development of NBGS can improve the screening efficiency of newborn genetic diseases, early detection, and early treatment, providing fertility guidance for the family of the patient children and enhancing the fertility rate. The experience of China’s NBGS can also be used for research in other countries to promote global health as a model study.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13023-022-02474-8.

Acknowledgements
We thank all individuals for participating in this investigation.

Author contributions
YS and TJ designed the research and made the final version of the manuscript; XW and XWG designed the questionnaire, analyzed data and wrote the manuscript with contributions from all the authors; YWY and DYH collected the samples; ZLZ, YHL and PYY involved in the test. All authors read and approved the final manuscript.

Funding
This work was supported by General project of Nanjing Medical Science and Technology Development Fund (No. YXK19118), National Key Research and Development Project (No. 2018YFC1002400) and Science and Technology Development Project of Nanjing Medical University (NMUB2019215, NMUB2020122).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was reviewed and approved by the Ethics Committee of the Nanjing Maternity and Child Health Care Hospital affiliated with the Nanjing Medical University. Written informed consent was obtained by all the participants.

Consent for publication
All the authors agreed to publish our work on this journal.

Competing interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 16 December 2021 Accepted: 13 August 2022 Published online: 26 August 2022

References
1. Martinez-Morillo E, Prieto Garcia B, Alvarez Menendez FV. Challenges for Worldwide Harmonization of Newborn Screening Programs. Clin Chem. 2016;62:689–98.
2. Serving the family from birth to the medical home. Newborn screening: a blueprint for the future—a call for a national agenda on state newborn screening programs. Paediatrics. 2000;106:389–422.
3. Sahai I, Marsden D. Newborn screening. Crit Rev Clin Lab Sci. 2009;46:55–82.
4. Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med. 2003;348:2304–12.
5. Ozben T. Expanded newborn screening and confirmatory follow-up testing for inborn errors of metabolism detected by tandem mass spectrometry. Clin Chem Lab Med. 2013;51:157–76.
6. Ombrone D, Giocalierr E, Forini G, Malvagia S, la Marca G. Expanded newborn screening by mass spectrometry: new tests, future perspectives. Mass Spectrom Rev. 2016;35:71–84.
7. Lehota DC, Hall P, Lepage J, Eshchorst JC, Etter ML, Greenberg CR. LC-MS/MS progress in newborn screening. Clin Biochem. 2011;44:21–31.
8. Ferreira CR, Rahmann S, Keller-M, Zschoeckle J, Group IA. An international classification of inherited metabolic disorders (ICIMD). J Inherit Metab Dis. 2021;44:164–77.
9. Waisbren SE, Albers S, Amato S, Ampola M, Brewster TG, Demmer L, et al. Effect of expanded newborn screening for biochemical, genetic disorders on child outcomes and parental stress. JAMA. 2003;290:2564–72.
10. Liu Y, Kang L, Li D, Jin Y, Song J, Li H, et al. Patients with cobalamin G or J defect missed by the current newborn screening program: diagnosis and novel mutations. J Hum Genet. 2019;64:305–12.
11. Tong F, Wang J, Xiao R, Wu BB, Zou CC, Wu DW, et al. Application of next-generation sequencing in the screening of monogenic diseases in China, 2021: a consensus among Chinese newborn screening experts. World J Pediatr. 2022;6:66.
12. Holm IA, Agrawal PB, Ceyhan-Birsoy O, Christensen KD, Fayer S, Frankel LA, et al. The BabySeq project: implementing genomic sequencing in newborns. BMC Pediatr. 2018;18:225.
13. Wojcik MH, Zhang T, Ceyhan-Birsoy O, Genetti CA, Lebo MS, Yu TW, et al. Discordant results between conventional newborn screening and genomic sequencing in the BabySeq Project. Genet Med. 2021;6:66.
14. Milko LV, Rini C, Lewis MA, Butterfield RM, Lin FC, Paquin RS, et al. Evaluating parents’ decisions about next-generation sequencing for their child in the NC NEXUS (North Carolina Newborn Exome Sequencing for Universal Screening) study: a randomized controlled trial protocol. Trials. 2018;19:344.
15. Roman TS, Crowley SB, Roche MJ, Foreman AKM, O’Daniel JM, Seifert BA, et al. Genomic sequencing for newborn screening: results of the NC NEXUS project. Am J Hum Genet. 2020;107:596–611.
16. Adhikari AN, Gallacher RC, Wang Y, Currier RJ, Amatuni G, Bassaganya R, et al. The role of exome sequencing in newborn screening for inborn errors of metabolism. Nat Med. 2020;26:1392–7.
17. Hao C, Guo R, Hu X, Qi Z, Guo Q, Liu X, et al. Newborn screening with targeted sequencing: a multicenter investigation and a pilot clinical study in China. J Genet Genomics. 2021;6:66.
18. Ceyhan-Birsoy O, Machini K, Lebo MS, Yu TW, Agrawal PB, Parad RB, et al. A curated gene list for reporting results of newborn genomic screening. Genet Med. 2017;19:809–18.
19. Ceyhan-Birsoy O, Murry JB, Machini K, Lebo MS, Yu TW, Fayer S, et al. Interpretation of genomic sequencing results in healthy and ill newborns: results from the BabySeq project. Am J Hum Genet. 2019;104:76–93.
20. Shan D, Qiu PY, Wu YY, Chen Q, Li AL, Ramadoss S, et al. Pregnancy outcomes in women of advanced maternal age: a retrospective cohort study from China. Sci Rep. 2018;8:12239.
21. Frederiksen LE, Ernst A, Brix N, Braskhøj Lauridsen LL, Roos L, Ramlau‑Hansen CH, et al. Risk of adverse pregnancy outcomes at advanced maternal age. Obstet Gynecol. 2018;131:457–63.
22. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam. 1968;65:281–393.
23. Downie L, Halliday J, Lewis S, Amor DJ. Principles of genomic newborn screening programs: a systematic review. JAMA Netw Open. 2021;4:e211436.
24. Timmermans S, Buchbinder M. Patients-in-waiting: living between sickness and health in the genomics era. J Health Soc Behav. 2010;51:408–23.
25. Wang X, Wang Y-Y, Hong D-Y, Zhang Z-L, Li Y-H, Yang P-Y, et al. Combined genetic screening and traditional biochemical screening to optimize newborn screening systems. Clin Chim Acta. 2022;528:44–51.
26. VanNoy GE, Genetti CA, McGuire AL, Green RC, Beggs AH, Holm IA, et al. Challenging the current recommendations for carrier testing in children. Paediatrics. 2019;143:S27–32.

27. Pereira S, Smith HS, Frankel LA, Christensen KD, Islam R, Robinson JO, et al. Psychosocial effect of newborn genomic sequencing on families in the babyseq project: a randomized clinical trial. JAMA Pediatr. 2021;175;1132–41.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.